Recursion Pharmaceuticals (RXRX) stock rises after J.P. Morgan upgraded the biotech, citing a $1B+ sales potential for the ...

RXRX Stock jumps after JPMorgan upgrade and trial data boost, fueling investor optimism in Recursion’s AI drug discovery ...

Earlier in December 2025, Recursion Pharmaceuticals reported positive Phase 1b/2 TUPELO trial data for REC-4881 in familial adenomatous polyposis, showing rapid and durable reductions in polyp burden ...

The simulation hypothesis—the idea that our universe might be an artificial construct running on some advanced alien computer ...

Cornered in a part of Downtown Los Angeles swamped in contemporary art museums and performance centers, REDCAT has become a ...

In 2025, Anthropic will grow from $1 billion to $9 billion in ARR (annual recurring revenue). OpenAI, meanwhile, will go from ...

Skills—a capability that allows users to teach Claude repeatable workflows—was introduced in October, and now Anthropic is ...

Three recent graduates from the MSU photo program noticed a glaring gap in the photo-journal world. While there has been ...

The staff at the Center for a New American Security dove into researching some of the most pressing and hard-hitting national ...

The MM+M editorial team was heartened by the progress made treating Alzheimer’s disease, the case of KJ Muldoon and ...

C compiler, LustreC, into a generator of both executable code and associated specification. Model-based design tools are ...